Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients From 6 to Less Than 18 Years of Age With Moderate-to-Severe Plaque Psoriasis
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 12 Feb 2019
At a glance
- Drugs Ixekizumab (Primary)
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Acronyms Ixora-peds
- Sponsors Eli Lilly and Company
- 28 Jan 2019 Status changed from recruiting to active, no longer recruiting.
- 14 Jan 2019 Planned primary completion date changed from 14 Nov 2019 to 7 Feb 2019.
- 21 Aug 2018 Planned End Date changed from 3 Jun 2021 to 11 Jun 2021.